The fictional drug scandal in 'The Fugitive' raises important questions about the pharmaceutical industry's regulatory framework and operational integrity.
If such a scandal were to occur in reality, it could expose vulnerabilities in drug approval processes and supply chain management, impacting both manufacturers and healthcare providers.
Moreover, the implications for public trust in pharmaceutical companies and regulatory bodies could be significant, necessitating a reevaluation of compliance measures and oversight mechanisms.